N
Nobuyuki Ide
Researcher at Sysmex Corporation
Publications - 3
Citations - 68
Nobuyuki Ide is an academic researcher from Sysmex Corporation. The author has contributed to research in topics: Immunoassay & Antigen. The author has an hindex of 2, co-authored 3 publications receiving 20 citations.
Papers
More filters
Journal ArticleDOI
A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies.
Kenta Noda,Kouki Matsuda,Shigehiro Yagishita,Kenji Maeda,Yutaro Akiyama,Junko Terada-Hirashima,Hiromichi Matsushita,Satoshi Iwata,Kazuto Yamashita,Yusuke Atarashi,Shunsuke Watanabe,Nobuyuki Ide,Tomokazu Yoshida,Norio Ohmagari,Hiroaki Mitsuya,Hiroaki Mitsuya,Akinobu Hamada +16 more
TL;DR: In this article, the authors developed a diagnostic test that detects SARS-CoV-2 IgG and IgM with high quantitativeness and reproducibility and low interference.
Journal ArticleDOI
Establishment and characterization of a fucosylated α-fetoprotein-specific monoclonal antibody: a potential application for clinical research.
Yuriko Egashira,Masatoshi Suganuma,Yukiko Kataoka,Yukiko Higa,Nobuyuki Ide,Koichi Morishita,Yoshihiro Kamada,Jianguo Gu,Koji Fukagawa,Eiji Miyoshi +9 more
TL;DR: The novel glycan antibody, FasMab, is a promising tool to study fucosylated AFP with clinical and basic research applications and demonstrated its potential clinical application.
Journal ArticleDOI
A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer.
Yumiko Sakai,Koji Kurose,Kanako Sakaeda,Hirotaka Abo,Yusuke Atarashi,Nobuyuki Ide,Toshiyuki Sato,Eiichiro Kanda,Minoru Fukuda,Toru Oga,Kenta Noda,Mikio Oka +11 more
TL;DR: In this article, a fully automated immunoassay system was developed to predict clinical benefits with anti-programmed cell death-1 (PD-1) antibodies (Abs) in non-small-cell lung cancer (NSCLC) treatment.